Home » Quotient, KWS partner in antimicrobial drug discovery
Quotient, KWS partner in antimicrobial drug discovery
May 10, 2011
Two U.K.-based providers of early-stage and other drug development services, Quotient Bioresearch and KWS BioTest, have partnered to offer coordinated “plate to patient” support for clients engaged in the discovery and development of new antimicrobial agents, according to Pharma Times.
As part of the agreement, Quotient and KWS will provide screening of anti-infectives from in vitro activity assays, efficacy testing and resistance profiling through to validated models of human disease, surveillance and clinical investigations.
The partnership will enable Quotient and KWS to carry out larger integrated studies in the sector.
Upcoming Events
-
21Oct